Wandercraft Launches Eve, the First Self-Balancing Personal Exoskeleton, in the U.S.
Wandercraft announced the U.S. commercial launch of Eve on September 17, 2026, describing it as the world's first FDA-cleared self-balancing personal exoskeleton. The device makes hands-free upright mobility available to eligible wheelchair users living with spinal cord injuries at any level who can manually operate its controller. The launch was marked at an event in New York City held with the United Spinal Association as the organization celebrates its 80th anniversary, and included the first public stand-up demonstration of the device.
Unlike exoskeletons that rely on crutches or a walker for balance, Eve uses self-balancing technology powered by physical AI so that users can stand and move upright with their hands free to reach, carry objects, prepare food and open doors. The company states that Eve is intended to complement, not replace, a wheelchair. Wandercraft says it is the first FDA-cleared device in this category without restrictions tied to the neurological level of spinal cord injury, expanding eligibility to adults who can safely operate the controller.
Eve is available by prescription only. Eligible individuals begin with a clinical evaluation and trial, and after a physician's order the device is individually fitted and manufactured for each user. Each user then completes a personalized training program with a companion before delivery, with ongoing support afterward. Wandercraft says the device is intended for use on level indoor surfaces and immediately adjacent outdoor areas such as patios and terraces, under the supervision of a trained companion, and is not intended for stairs, slopes, ramps, wet or icy ground, crowded areas, parking lots or roadways.
Reimbursement pathways are in place for qualifying users. Medicare covers qualifying personal exoskeletons as custom-fitted orthoses under HCPCS billing code K1007, subject to individual coverage requirements, and the company says personal exoskeletons are also covered by the Department of Veterans Affairs through USVetServ and by workers' compensation programs. National Seating & Mobility, Wandercraft's exclusive Complex Rehabilitation Technology distribution partner for Eve, will support evaluation, education, access and delivery through a network of more than 180 locations, while Good Shepherd Rehabilitation expands access in Pennsylvania's Lehigh Valley. Users can experience Eve at Walk in New York by Wandercraft, with a second location, Walk in Miami, expected to open in November.
The FDA clearance behind the launch was granted on August 11, 2026, and was supported by a three-site clinical trial conducted at the James J. Peters Department of Veterans Affairs Medical Center in the Bronx, New York, Kessler Foundation in West Orange, New Jersey, and Walk in New York. Wandercraft says participants reported improvements in health status, psychological well-being, endurance during daily activities, lower-limb spasticity and sitting balance, with some also reporting better sleep quality and bladder and bowel function. The company, whose Atalante X rehabilitation exoskeleton is used at more than 150 inpatient and outpatient centers worldwide, says its access team is continuing to work with payers, including private insurers, to widen coverage.